Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Coley begins trial of Actilon in hepatitis
The phase II clinical trial is expected to enroll 90 adults with genotype 1 hepatitis C virus (HCV) who have failed previous therapy with the current standard of
The phase II clinical trial is expected to enroll 90 adults with genotype 1 hepatitis C virus (HCV) who have failed previous therapy with the current standard of
Isotretinoin, marketed by Roche as Accutane, is approved to treat severe recalcitrant nodular acne. The drug is highly effective in the treatment of this form of acne, but
The state-of-the-art laboratory will allow Tepnel to consolidate its existing pharmaceutical services business into a single location, with its primary function being the analysis of therapeutic proteins, including
The contracts are worth GBP33 million and will help prepare for and reduce the impact of a possible flu pandemic. The vaccine will be used to carry out
Erbitux is currently licensed in the European Union for metastatic colorectal cancer after being first approved in Switzerland in December 2003. Germany’s Merck licensed the right to market
The French drug maker revealed its forecast for Acomplia upon posting fourth quarter financial results. Originally slated for a second quarter release, the drug is now more likely
Patient enrollment in the so-called Genasis trial was expected to be complete by the end of March. However, the company has been slow to reach its target number
NX-1207 has completed two earlier phase I and II trials where the drug produced on average over 23% prostate shrinkage in one month with minimal side effects. Overall
ZIO-201 is the active metabolite of ifosfamide, a frequently used, yet highly toxic, treatment for sarcoma. ZIO-201 is designed to deliver therapeutic activity at higher doses with less
Nycomed acquired the rights to develop and market the drug in Europe from NPS Pharmaceuticals in 2004. NPS Pharmaceuticals has filed a similar new drug application for clearance